Cagrilintide
Long-acting analogue
Overview
Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide ("CagriSema").
Source: English Wikipedia, "Cagrilintide".
What the Evidence Shows
A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits.
Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment. In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss ≥15%, compared to approximately 1 in 20 participants (4.7%) who received placebo.
^ Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B, et al. (2024). "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism. 28 (5): 436–444. doi:10.4103/ijem.ijem_45_24. PMC 11642503. PMID 39676787.
^ "REDEFINE 1". ^ Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Lehmann EW, Pietiläinen KH, et al. (2025). "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine. 393 (7): 635–647. doi:10.1056/NEJMoa2502081. PMID 40544433.